Jeannett Hvidkjær joins Visiopharm board
Visiopharm today announced that Jeannett Hvidkjær has been appointed to its board.
Hvidkjær brings extensive experience from her current position as CEO and Group CFO in LTP Group A/S – a privately held, global business and manufacturing partner for demanding Sport & Outdoor Garments and Contract Furniture brands – as well as her previous position for thirteen years as EVP, CFO for Cooper Surgical Denmark (Origio A/S) – the global leader in IVF and reproductive genetics and part of The Cooper Companies (S&P 500; Symbol COO).
Hvidkjær started her professional carrier in audit services with EY. Hvidkjær has a broad strategic expertise, an international perspective and in-depth knowledge in various areas, within finance and accounting, M&A, establishment of international operations, as well as compliance and risk management.
Hvidkjær holds a bachelor in Business Economics and Accounting, and certificates from INSEAD for Executive Management Programme in Strategy, Innovation and Leadership and Executive Board Programme, as well as various compliance trainings.
Jeannett Hvidkjær said:
“Visiopharm is a unique company with a comprehensive experience and knowledge in AI-driven precision pathology. The technology effectively addresses critical needs in cancer diagnostics and drug development research. I look very much forward to supporting the company in realising its ambitions and I consider it to be a great responsibility and a privilege to become part of Visiopharm’s journey onwards in the market for AI-driven digital pathology solutions.”
Michael Grunkin, CEO, Visiopharm said:
“Strengthening the board with the competencies Jeannett represents, is very timely as we are embarking on a next phase of our journey. The collaboration is already off to a strong start, and I very much look forward to benefit from her extensive financial experience as we continue to scale.”